We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+29.83%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$2.21B
AUM Growth
+$276M
Cap. Flow
-$34.2M
Cap. Flow %
-1.55%
Top 10 Hldgs %
39.41%
Holding
128
New
23
Increased
32
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
TRAX
First Tracks Biotherapeutics
TRAX
+$38M
2
ROIV icon
Roivant Sciences
ROIV
+$28.1M
3
AVTX icon
Avalo Therapeutics
AVTX
+$24.6M
4
RVMD icon
Revolution Medicines
RVMD
+$21.9M
5
INSM icon
Insmed
INSM
+$20.6M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$55.6M
2
ACLX
Arcellx
ACLX
+$41.7M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$34.2M
4
TERN
Terns Pharmaceuticals
TERN
+$29.7M
5
APGE icon
Apogee Therapeutics
APGE
+$26.8M

Sector Composition

Rank Sector Weight
1 Healthcare 89.73%
2 Miscellaneous 9.21%
3 Financials 1.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
51
Teva Pharmaceuticals
TEVA
$42.7B
$12.7M 0.57%
374,000
-1,026,000
-73% -$34.2M
MANE
52
Veradermics Inc
MANE
$4.08B
$12.3M 0.56%
100,000
+30,000
+43% +$2.81M
ARWR icon
53
Arrowhead Research
ARWR
$12.2B
$12.2M 0.55%
150,000
-50,000
-25% -$3.69M
TSHA icon
54
Taysha Gene Therapies
TSHA
$1.81B
$11.9M 0.54%
1,750,000
+750,000
+75% +$4.44M
DMRA
55
Damora Therapeutics
DMRA
$1.73B
$11.1M 0.5%
425,000
-25,000
-6% -$605K
EPRX
56
Eupraxia Pharmaceuticals
EPRX
$496M
$10.9M 0.49%
1,650,000
+60,995
+4% +$421K
VERA icon
57
Vera Therapeutics
VERA
$2.52B
$10.7M 0.48%
250,000
– –
PRQR icon
58
ProQR Therapeutics
PRQR
$295M
$10.3M 0.47%
5,543,936
+3,089,658
+126% +$5.09M
NAMS icon
59
NewAmsterdam Pharma
NAMS
$3.09B
$9.32M 0.42%
275,000
– –
KRRO icon
60
Korro Bio
KRRO
$171M
$9.32M 0.42%
706,904
– –
QURE icon
61
CALL
uniQure
QURE
$3.11B
$9.21M 0.42%
200,000
-100,000
-33% -$2.62M
AVR
62
Anteris Technologies
AVR
$850M
$8.99M 0.41%
912,397
– –
ZURA icon
63
Zura Bio
ZURA
$563M
$8.64M 0.39%
1,464,303
-1,100,000
-43% -$5.24M
QURE icon
64
uniQure
QURE
$3.11B
$8.06M 0.36%
+175,000
New +$4.58M
ASND icon
65
Ascendis Pharma A/S
ASND
$17.8B
$8M 0.36%
30,000
-65,000
-68% -$15.2M
IBIO icon
66
iBio
IBIO
$83.6M
$7.01M 0.32%
4,007,881
+900,681
+29% +$1.61M
GENB
67
Generate Biomedicines
GENB
$2.1B
$6.75M 0.31%
400,000
+50,000
+14% +$681K
EVMN
68
PUT
Evommune Inc
EVMN
$436M
$6.65M 0.3%
+500,100
New +$11.6M
TYRA icon
69
Tyra Biosciences
TYRA
$1.48B
$6.39M 0.29%
200,012
-57,500
-22% -$1.9M
SLGL icon
70
Sol-Gel Technologies
SLGL
$230M
$6.29M 0.28%
84,900
+49,900
+143% +$3.66M
SABS icon
71
SAB Biotherapeutics
SABS
$338M
$5.95M 0.27%
1,525,000
+950,000
+165% +$3.53M
MGNX icon
72
MacroGenics
MGNX
$271M
$5.62M 0.25%
1,216,606
+716,606
+143% +$2.71M
CRSP icon
73
CRISPR Therapeutics
CRSP
$5.46B
$5.45M 0.25%
100,000
-50,000
-33% -$2.64M
NAMSW icon
74
NewAmsterdam Pharma Warrant
NAMSW
$66.4M
$5.34M 0.24%
245,000
– –
ASMB icon
75
Assembly Biosciences
ASMB
$736M
$5.22M 0.24%
+190,000
New +$5.17M
1 2
3
4 5

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Affinity Asset Advisors held 128 positions worth $2.21B, up 14% from $1.94B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Affinity Asset Advisors's Q2 2026 filing shows 23 new, 32 increased, 32 reduced and 15 closed positions. Its largest new stake was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M. The largest sale was Centessa Pharmaceuticals, an estimated $55.6M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.

  • Affinity Asset Advisors's largest Q2 2026 buy was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M.
  • Affinity Asset Advisors added most to Roivant Sciences in Q2 2026, an estimated $28.1M increase.
  • Affinity Asset Advisors's biggest Q2 2026 reduction was Teva Pharmaceuticals, cutting an estimated $34.2M.
  • Affinity Asset Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $55.6M.
  • Affinity Asset Advisors's ten largest holdings make up 39% of its $2.21B portfolio in Q2 2026.
  • Affinity Asset Advisors opened 23 new positions and closed 15 in Q2 2026.
  • Affinity Asset Advisors's portfolio value rose 14% quarter-over-quarter to $2.21B.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.